Purpose. Our study is aimed at investigating the mechanism by which electroacupuncture (EA) promoted nerve regeneration by regulating the release of exosomes and exosome-mediated miRNA-21 (miR-21) transmission. Furthermore, the effects of Schwann cells- (SC-) derived exosomes on the overexpression of miR-21 for the treatment of PNI were investigated.

Methods. A sciatic nerve injury model of rat was constructed, and the expression of miR-21 in serum exosomes and damaged local nerves was detected using RT-qPCR after EA treatment. The exosomes were identified under a transmission electron microscope and using western blotting analysis. Then, the exosome release inhibitor, GW4869, and the miR-21-5p-sponge used for the knockdown of miR-21 were used to clarify the effects of exosomal miR-21 on nerve regeneration promoted by EA. The nerve conduction velocity recovery rate, sciatic nerve function index, and wet weight ratio of gastrocnemius muscle were determined to evaluate sciatic nerve function recovery. SC proliferation and the level of neurotrophic factors were assessed using immunofluorescence staining, and the expression levels of SPRY2 and miR-21 were detected using RT-qPCR analysis. Subsequently, the transmission of exosomal miR-21 from SC to the axon was verified in vitro. Finally, the exosomes derived from the SC infected with the miR-21 overexpression lentivirus were collected and used to treat the rat SNI model to explore the therapeutic role of SC-derived exosomes overexpressing miR-21.

Results. We found that EA inhibited the release of serum exosomal miR-21 in a PNI model of rats during the early stage of PNI, while it promoted its release during later stages. EA enhanced the accumulation of miR-21 in the injured nerve and effectively promoted the recovery of nerve function after PNI. The treatment effect of EA was attenuated when the release of circulating exosomes was inhibited or when miR-21 was downregulated in local injury tissue via the miR-21-5p-sponge. Normal exosomes secreted by SC exhibited the ability to promote the recovery of nerve function, while the overexpression of miR-21 enhanced the effects of the exosomes. In addition, exosomal miR-21 secreted by SC could promote neurite outgrowth in vitro.

Conclusion. Our results demonstrated the mechanism of EA on PNI from the perspective of exosome-mediated miR-21 transport and provided a theoretical basis for the use of exosomal miR-21 as a novel strategy for the treatment of PNI.
Peripheral nerve injury (PNI) is a common clinical disease [1] that is usually caused by trauma, compression, ischemic, and metabolic disorders [2], leading to the loss of sensory and motor neural functions [3–5]. The regeneration of the injured nerve is usually slow and incomplete, while patients suffer from pain and from a lower quality of life after PNI [6]. As a refractory disease, patients with PNI suffer with impairment of function even after the surgical treatment [7–11], for example, 40% of motor function was recovered by autologous nerve transplantation [12]. Thus, researchers have been trying to develop nonsurgical methods for the management of PNI. Electroacupuncture (EA) is defined as a combination of electrical stimulation with acupuncture needles and is capable of promoting the regeneration of the transected median nerve in rats [13] and increasing neuronal stem cell proliferation [14]. We have confirmed that EA could promote Schwann cells (SC) proliferation and the release of neurotrophic factors (NTFs), including brain-derived neurotrophic factor (BDNF) [15] and nerve growth factor (NGF) [16] after PNI.

miRNAs are involved in a wide range of biological processes [17–20] through base pairing with complementary sequences within mRNA [21]. miRNAs have been regarded as important diagnostic and therapeutic targets [22], and they can regulate many target genes [23–25]. Moreover, EA provides a multichannel, multitarget, and multilink method of treatment [26–30]. Therefore, we aimed to elucidate new mechanisms of EA treatment for PNI via the regulation of miRNAs. It has been proven that the expressions of many different miRNAs are changed after PNI [15, 31–34], indicating its association with the occurrence and development of the nervous system [35,36], miRNA-21 (miR-21) expression is upregulated following PNI in the serum [37], local injury tissue [38], and dorsal root ganglion (DRG) [39]. Moreover, miR-21 is strongly associated with nerve repair [40], neuron survival [41], and neuropathic pain [42]. It has been reported that miR-21 can promote the proliferation and survival of SC [43]. As a well-known key player involved in PNI repair, SC is responsible for the formation of the myelin sheath that protects axons and material exchange with the axons [44]. As an excellent drug carrier and new diagnostic marker and therapeutic agent [45–47], exosomes play a significant role in the myelinization and nerve regeneration after PNI by transferring proteins or nucleic acids [48, 49]. Current research indicates that exosome-derived stem cells may cause neuroprotective effects, remyelination, and recovery of function after PNI [50]. EA has been found to increase the abundance of exosomes and regulate miRNA and circular RNA in exosomes found in blood circulation [51, 52]. Therefore, a PNI model of rats was constructed to investigate the mechanism by which EA promotes the structural and functional recovery through the delivery of exosome-mediated miR-21, which provides a promising strategy for the treatment of PNI.

2. Materials and Methods

2.1. Animal Model and Tissue Preparation. SPF-grade male Wistar rats (body weight 260 ± 20 g) were provided by the Animal Experimental Center of Shanghai University of Traditional Chinese Medicine.

2.1.1. Method 1. After a week of adaptive feeding, the rats were anesthetized using 1% pentobarbital (45 mg/kg) and randomly divided into 3 groups (n = 10 in each group). For the sham group (Sham), the right sciatic nerve was exposed and the skin was sutured with the nerve left intact. For the model group (Model), the right sciatic nerve was exposed, and the adventitial layer was sutured after transection injury, followed by skin suture. For the electroacupuncture group (EA), acupuncture needles were inserted into the acupoints, “Huantiao” (GB30) and “Zusanli” (ST36), and connected to positive and negative poles, respectively. Thereafter, the rats were treated using EA after modeling for 7 days (intermittent wave, 20 min each day at an electric current intensity that caused a slight muscle twitch was selected). After treatment, blood was collected from the abdominal aorta and centrifuged at 3000 g at 4°C for 15 min to isolate serum. Total RNA from injured right sciatic nerve was extracted using NucleoZOL (MN, Düren, Germany).

2.1.2. Method 2. After the rats were anesthetized, as described above, the distal segment of the right sciatic nerve (intact or injured) was exposed and transfected with 25 μl of pCT-CD63-GFP plasmid-containing the lentivirus (OBiO Technology, Shanghai, China) and 25 μl of Matrigel (BD Biosciences, Bedford, MA), and then, the skin was sutured. At 7 days after transfection, cross-sections of the right sciatic nerve (10 μm) were prepared after being fixed with 4% paraformaldehyde and embedded with OCT (Sakura Finetek, Tokyo, Japan).

2.1.3. Method 3. After the model was created, as described in Method 1, the rats were randomly divided into 4 groups (n = 10 in each group). For the model group (Model), the distal segment of the injured nerve was injected with 25 μl of Matrigel and 25 μl of the lentivirus produced using an empty plasmid (OBiO Technology). The rats also received an injection of 3.75% dimethylsulphoxide (DMSO; Sigma) diluted in saline every 2 days for 3 weeks. For the electroacupuncture group (EA), the lentivirus was injected as the model group, and EA was performed with 1 day rest every 7 days for 3 weeks (same parameter as Method 1). Similar to the model group, these rats also received an injection of DMSO. For the electroacupuncture + GW4869 group (EG), the lentivirus was injected, like the model group, and EA was performed with 1 day rest every 7 days for 4 weeks (same parameters as Method 1), and the rats received an injection of 1 mg/kg GW4869 dissolved in 3.75% DMSO diluted with saline every 2 days for 3 weeks. For the electroacupuncture + miR-21-5p-sponge group (ES), the distal segment of the injured nerve was injected with 25 μl of Matrigel and 25 μl of the lentivirus produced using the miR-21-5p-sponge expression plasmid (OBiO Technology, Shanghai, Germany)
At 3 weeks after the treatment, total RNA of the proximal injured nerve was extracted using NucleoZOL. Cross-sections of the distal right sciatic nerve (10 μm) were prepared after being fixed using 4% paraformaldehyde and embedded in OCT.

2.1.4. Method 4. After modeling as mentioned in Method 1, the rats were randomly divided into 3 groups (n = 10 in each group). For the model group (Model), the distal segment of the injured nerve was injected with 25 μl of Matrigel and 25 μl of PBS. For the SC-derived exosomes group (EXO-MC), the distal segment of the injured nerve was injected with 25 μl of Matrigel and 25 μl of SC-derived exosomes (15 μg). For the SC-derived exosomes with the overexpression of miR-21 (EXO-miR-21), the distal segment of the injured nerve was injected with 25 μl of Matrigel and 25 μl of SC-derived exosomes with the overexpression of miR-21 (15 μg). At 3 weeks after treatment, total RNA of the proximal injured nerve was extracted, and 10 mm thick frozen slices of the distal injured nerve were prepared.

2.2. Detection of Sciatic Nerve Function Recovery Index. The general condition of the rats was evaluated every week: wounds, skin on the feet, and the activities of the right hind limb muscles and joints were recorded. Three different methods were used to determine the sciatic nerve function recovery index before the rats were sacrificed.

2.2.1. Method 1. For nerve conduction velocity recovery rate (NCV), the NCV of the bilateral sciatic nerve was measured, as previously described [15]. In brief, the stimulating electrode and the receiving electrode were connected to the proximal and distal ends of the sciatic nerve, respectively, using the copper handle of the acupuncture needle. A RM6240 Biological Signal Collecting System (Chengdu Instrument Factory, Chengdu, China) was used to trigger an electrical stimulation and record compound motor action potentials (CMAPs), while nerve conduction velocity was measured based on the distance between electrodes and the time required for electrical stimulation delivery. The recovery of NCV was subsequently calculated through the ipsilateral/contralateral ratio.

2.2.2. Method 2. For sciatic nerve function index (SFI), the rats were allowed to freely walk on white paper after their hind paws were dipped in ink. PL indicates the length from the heel to the toe, and TS indicates the toe-spread between toes 2 and 4 (N: normal side; E: experimental side). SFI was calculated as follow: SFI = −38.3 × (EPL − NPL)/NPL + 109.5 × (ETS − NTS)/NTS + 13.3 × (EIT − NIT)/NIT − 8.8. A value closer to 0 indicated better recovery of neurological function.

2.2.3. Method 3. For wet weight ratio of the gastrocnemius muscle (WWRG), the wet weight of the bilateral gastrocnemius muscles was measured after being carefully dissociated. WWRG was calculated using the ipsilateral/contralateral ratio.

2.3. Isolation of Exosomes. The exosomes were isolated through ultracentrifugation (CS120FNX, HITACHI, Japan).

2.3.1. Serum. The supernatant was harvested after being centrifuged at 10,000 g for 30 min and was passed through a 0.22 μm syringe filter and then spun at 100,000 g for 70 minutes. The pellet was resuspended in cold PBS (0.1 M, pH 7.4) after discarding the supernatant and was ultracentrifuged at 100,000 g for 70 min again; then, the pellet (exosomes) was resuspended in 100 μl of PBS and stored in aliquots at −80°C.

2.3.2. Cell Culture Supernatant. The supernatant was centrifuged at 300 g for 10 min to remove cell components and then at 2,000 g for 10 min to remove dead cells. After being centrifuged at 10,000 g for 30 min to eliminate cell debris, the supernatant was subjected to ultracentrifugation for 70 min at 100,000 g. The pellet was resuspended in cold PBS and ultracentrifuged again at 100,000 g for 70 min. Then, the pellet containing exosomes was resuspended in PBS and stored at −80°C.

All operations were performed at 4°C. Exosome concentration was quantified by conducting a Bradford assay (Thermo Fisher Scientific, Colorado, USA).

2.4. Characterization of Exosomes

2.4.1. Method 1. For transmission electron microscope (TEM), exosomes were placed on copper and treated with phosphotungstic acid for negative staining. A Tecnai G2 Spirit TEM (Thermo Fisher Scientific) was used to observe the morphology of the exosomes.

2.4.2. Method 2. For western blotting (WB) analysis, exosomes were loaded onto 10% SDS-PAGE gel after protein denaturation. 5% skimmed milk powder was used to block nonspecific binding sites after the protein was transferred onto a polyvinylidene fluoride (PVDF; Millipore) membrane. The blots were incubated with the primary antibodies, CD9 (1:2000; Abcam ab92726, Cambridge, MA) and CD63 (1:1000; Abcam ab108950), overnight at 4°C. After the membrane was washed with Tris-Buffered Saline and Tween 20, it was incubated with appropriate HRP conjugated secondary antibodies at room temperature for 1 h. The blots were visualized using an electrochemiluminescence reagent (Millipore, Bedford, MA, USA).

2.4.3. Method 3. For nanoparticle tracking analysis (NTA), exosome particle size and concentration were measured using nanoparticle tracking analysis (NTA) using ZetaView PMX 110 (Particle Metrix, Meerbusch, Germany) and corresponding software, ZetaView 8.04.02. The isolated exosome samples had appropriately diluted using 1x PBS buffer, and the ZetaView system was calibrated using 110 nm polystyrene particles. The temperature was maintained at around 23-30°C.

2.5. Immunofluorescence Staining. The sections were washed with PBS, and the cell membrane was permeabilized using 0.5% Triton X-100. After blocking using normal goat serum, the samples were incubated with an appropriate primary
antibody overnight: Neurofilament 200 (NF200; Sigma-Aldrich N4142, MO, USA) diluted at 1:80, GFP (Abcam ab1218) diluted at 1:1000, Myelin Basic Protein (Abcam ab40390) diluted at 1:200, S-100α (Abcam ab11428) diluted at 1:200, NGF (Abcam ab6199) diluted at 1:100, BDNF (Abcam ab108319) diluted at 1:500, and glial cell line-derived neurotrophic factor (GDNF; Abcam ab18956) diluted at 1:50. The secondary antibodies used were goat anti-rabbit antibody Alexa 555 (Thermo A-21428) diluted at 1:800, goat anti-rabbit antibody Alexa 488 (Thermo A-11034), and goat anti-mouse antibody Alexa 488 (Thermo A-11001) diluted at 1:800, while DAPI (Sigma-Aldrich) was used to stain the nuclei.

2.6. RNA Extraction

2.6.1. Nerve. 500 μl of NucleoZOL was added to the sciatic nerve, and the tissue was homogenized using a tissue homogenizer. The lysate was incubated at room temperature for 15 minutes and centrifuged at 12,000 g for 15 min after 200 μl of RNase-free water was added, and the mixture was shaken vigorously for 15 s. Then, 500 μl of the supernatant was collected in a new centrifuge tube, and 200 μl of 75% ethanol was added. The mixture was incubated at room temperature for 10 min and then centrifuged at 12,000 g for 8 min. The precipitate was collected to obtain long-stranded RNA. Then, the supernatant was transferred, and 500 μl of isopropanol was added and then centrifuged at 12,000 g for 15 min. Thereafter, the precipitate was collected to obtain short-stranded RNA.

2.6.2. Exosomes. miRNeasy Serum/Plasma Advanced Kit (Qiagen 217184, Hilden, Germany) was used to extract RNA from the exosomes, as described in the manufacturer’s instructions.

2.7. RT-qPCR

2.7.1. miRNA. First-strand cDNA was synthesized using a miRcute Plus miRNA First-Strand cDNA Kit (Tiangen Biotech KR211, Beijing, China), while qPCR was performed using a miRcute Plus qPCR Kit (SYBR Green; Tiangen Biotech FP411). The miR-21-5p primer sequence used was GTAGCTTATCAGACTGATGTTGA, and the internal reference U6 primer sequence used was CTCGCTTCGGCAGCGAC. The miR-39 primer was used as external reference (Qiagen). The amplification reaction conditions were as follows: 15 min at 95°C, followed by 40 cycles of denaturation at 94°C for 20 s, followed by the annealing and extension of the primers at 60°C for 30 s. The melting curves were constructed, and each reaction was performed in triplicate. The RT-qPCR data were analyzed using the ΔΔCT method.

2.7.2. mRNA. First-strand cDNA was generated using a FastKing gDNA Dispelling RT SuperMix (Tiangen Biotech KR118), while qPCR was performed using SuperReal Pre-Mix Plus (SYBR Green; Tiangen Biotech FP205). The primer sequences used were as follows: sprouty homolog 2 (SPRY2): TGAAAGACTCCACGGTCTGC, CAGTGAGACTGGCTTC; sprouty homolog 1 (SPRY1): TGAAAGACTCCACGGTCTGC, CAGTGAGACTGGCTTC; glyceraldehyde-3-phosphate dehydrogenase (GAPDH): AGTACTTACCACGGCAAG, GAGATGTGATGGGTTC; DNA Methyltransferase 3A (DNMT3A): CAGCAAAAGTGAGACCATTA, AACACCCCTTCCATTTAC; and the internal reference, glyceraldehyde-3-phosphate dehydrogenase (GAPDH): ATGACTTACCACGGCAAG, GAGATGTGATGGGTTC. All primer sequences were synthesized by Sangon Biotech. The reaction conditions were as follows: 15 min at 95°C, followed by 40 cycles of denaturation at 95°C for 10 s, annealing of primers at 52°C for 30 s, and extension at 72°C for 32 s. The melting curves were created, and each reaction was performed in triplicate. The data were analyzed using the ΔΔCT method.

2.8. Cell Culture. As a rat SC lineage, RSC96 cells purchased from Chinese Academy of Sciences were cultured in Dulbecco's Modified Eagle Medium (DMEM; Corning Cellgro) containing 10% fetal bovine serum (FBS; Gibco). For cell passage, the RSC96 cells were washed with PBS and treated with 2.5% trypsin (Corning Cellgro, Manassas, VA) to digest the cells. Then, the pellet was resuspended in fresh medium after being centrifuged at 1000 g for 5 min.

NG108-15 cells (ATCC, Manassas, VA) were cultured in DMEM supplemented with 10% FBS, 0.1 mM hypoxanthine (Sigma-Aldrich), 400 mM aminopterin (Sigma-Aldrich), and 16 μM thymidine (Sigma-Aldrich) to be used as neuron cell lineage. The protocol for cell passage was the same as that for RSC96, which is mentioned above.

2.9. Cell Transfection and Exosome Internalization Assays

2.9.1. Method 1. RSC96 cells were seeded on 0.4 μm Boyden chamber inserts (Corning) which were placed in 24-well plates (Corning). pCT-CD63-GFP plasmids were transfected into RSC96 cells using a Lipofectamine 3000 (Thermo) system after 24 h. The medium was changed 24 h after transfection, and the NG108-15 cells were seeded onto the bottom of a 24-well plate. After 3 days of cocultivation, the NG108-15 cells were fixed using 4% DEPC-PFA and immunofluorescence, and fluorescent in situ hybridization (IF-FISH) was performed.

2.9.2. Method 2. Exosome-free FBS was obtained through ultracentrifugation at 90,000 g for 16 h at 4°C to remove bovine exosomes. Then, the identity of the exosome-free FBS was verified using WB detection of the exosomal markers, CD9 and CD63. The RSC96 cells were cultured in DMEM containing 10% exosome-free FBS for 72 h, and the cell culture supernatant was collected to isolate the exosomes, as mentioned above. NG108-15 cells were seeded onto Nunc™ Glass Bottom Dishes (Thermo), and 96-well plate with DMEM containing 10% exosome-free FBS was added. After 24 h, the cells were divided into 4 groups, as follows. For negative control group (NC), 200 nM miR-21 inhibitor negative control (RiboBio Guangzhou, China) was transfected into NG108-15 cells using a Lipofectamine 3000 system. For negative control + exosomes group (NC + EXO), 200 nM miR-21 inhibitor negative control was transfected into NG108-15 cells, and 3 μg or 0.3 μg/well SC-derived exosomes were added into NG108-15 cells
cultured on Nunc Glass Bottom Dishes or 96-well plates, respectively. For miR-21 inhibitor group (IN), NG108-15 cells were transfected with 200 nM miR-21 inhibitors (Ribobio). For miR-21 inhibitor + exosomes group (IN+EXO), NG108-15 cells were transfected with 200 nM miR-21 inhibitors and 3 μg or 0.3 μg/well of SC-derived exosomes, which were added to the NG108-15 cells cultured on Nunc Glass Bottom Dishes or 96-well plates, respectively. Immunofluorescence staining of βIII-tubulin (1:200; Abcam ab18207) and CCK-8 (Dojindo, Kumamoto, Japan) was performed after 24 h. Immunofluorescence staining was performed, as mentioned above. For the CCK-8 assays, a 96-well plate was placed in the cell incubator for 2 h after 10 μl of CCK-8 working solution was added to each well. Then, the 450 nm OD value of each well was measured using a microplate reader (Synergy 2, BioTek, United States).

2.10. Immunofluorescence and Fluorescent In Situ Hybridization (IF-FISH). NG108-15 cells were washed with DEPC-PBS after being fixed using PFA. The following steps were performed, as instructed by the manufacturer (Focobio D-0010, Guangzhou, China). In brief, solutions A and B were added to the cells and allowed to incubate for 20 min and 15 min, respectively. After washing, a DEPC-PBS, hybridization buffer was added for prehybridization, and the mixture was left for 2 h at 55°C. During this time, the hybridization buffer was used to prepare 4 different probes that directly carried Cy3 fluorophore (Sangon Biotech, Shanghai, China): 30 nM U6 probe (positive control), 1200 nM miR-21 probe (target gene), 1200 nM scrambled probe (negative control), and hybridization buffer without probe (blank control). The sequences of the probes are as follows: TCAACATCAGTCTGATAAGCTA (miR-21), CACGAATTTGCGTGTCATCCTT (U6), and GTGTAAA (U6), and GTGTAA (U6), and GTGTAA (U6), and GTGTAA (U6), and GTGTAA (U6), and GTGTAA (U6). These probes were denatured at 85°C for 3 min and equilibrated at 37°C for 2 minutes. Each probe was added and hybridized at 37°C for 24 h after prehybridization. After being washed using a 1× washing buffer, immunofluorescence double staining of βIII-tubulin (1:200) and GFP (1:1000) was performed, as described above, using the corresponding secondary antibodies, donkey anti-rabbit antibody Alexa Fluor 350 (Thermo A-10039) and goat anti-mouse antibody Alexa 488.

3. Statistical Methods

All data are presented as the mean ± standard deviation, and statistical analyses were performed using the SPSS 22.0 software (SPSS, Chicago, USA). One-way analysis of variance (ANOVA) with Scheffe’s post hoc multiple-comparison analysis was used to analyze intergroup differences, and a P value of <0.05 was considered to indicate statistical significance.

4. Results

4.1. Dual-Directional Regulation of EA on Serum Exosomal miR-21. To investigate the possible involvement of exosomal miR-21 in EA treatment of PNI, a sciatic nerve transaction model was constructed (Supplementary Figure S1). The ultracentrifugation method was used to isolate exosomes from the serum at 7 d post-EA treatment. TEM demonstrated that the exosomes were cup-shaped (Figure 1(a)), and WB showed that the expressions of the exosome surface proteins, CD9 and CD63, were positive (Figure 1(b)). To confirm the success of exosome isolation, particle size was detected using NTA. Most exosomes showed a particle size of about 110-120 nm (Figure 1(c)). RT-qPCR was used to test the expression of miR-21 in exosomes. The expression level was significantly elevated in the model compared with the sham group, while its downregulation was observed after EA treatment, compared with the model group (Figure 1(d)). As U6 has not been fully established as an internal reference for exosomal RNA, the external reference miR-39 was used to further verify its expression. It was demonstrated that the expression of miR-21 showed a similar trend using both methods (Figure 1(e)). Interestingly, we found that the level of miR-21 was elevated after EA treatment, compared with the model group, at 21 d (Figure 1(f)). In the damaged local nerves, miR-21 expression was lower in the model group and higher in the EA group, compared with that of the sham group. In addition, EA treatment significantly elevated miR-21 expression, compared with the model group, at 7 d (Figure 1(g)) and 21 d (Figure 2(a)). Taken together, these data show that EA can not only regulate the expression of miR-21 in local injury but also exert a dual-directional regulation effect on serum exosomal miR-21 expression.

4.2. Exosomal miR-21 Participated in EA by Promoting the Recovery of Nerve Function and Regeneration. GW4869 and miR-21-5p-sponge-lentivirus were used to explore whether exosomal miR-21 is involved in the effect produced by EA. The expression of miR-21 in local injured tissue increased in the EA group, compared with that of the model group, and decreased in the EG and ES groups, compared with that of the EA group at 21 d (Figure 2(a)). The expression level of SPRY2, a target gene of miR-21, was opposite to the expression of miR-21 (Figures 2(b) and 2(c)). Moreover, the expression levels of GAP43 and DNMT3A, which are positively correlated with axon growth, were positively correlated with miR-21 expression (Figures 2(d)–2(f)). Severe
Figure 1: EA regulated the release of serum exosomal miR-21. (a) Exosomes (arrows) were observed under a transmission electron microscope, bar = 100 nm. (b) The surface markers of the exosomes, including CD9 and CD63, were detected using WB. (c) The particle size was detected using NTA. RT-qPCR was conducted to detect the relative expression level of miR-21 in the serum exosomes of rats in each group at 7 d with U6 used as the internal reference (d) or miR-39 used as an external reference (e). **P < 0.01 compared with the sham group; ## P < 0.01 compared with the model group. (f) RT-qPCR detection of miR-21 expression in serum exosomes at 21 d. **P < 0.01 compared with the model group. (g) RT-qPCR detection of the relative expression of miR-21 in locally injured nerves of rats at 7 d. *P < 0.05 compared with the sham group; ### P < 0.01 compared with the model group.
plantar ulcers were observed to have appeared in the EG and ES group at 21 d. In the EA group, there was no total absence, and no large-area ulcers were observed on the plantar, while the ulcer surface healed well without exudation (Supplementary Figure S2). Compared with the model group, EA treatment significantly increased NCV (Figure 3(a)), SFI (Figures 3(b) and 3(c)), and WWRG (Figure 3(d)) after 21 d, which indicated a higher sciatic nerve function recovery index. Additionally, the values of these 3 indicators were significantly downregulated in the EG and ES group, compared with the EA group. Immunofluorescence staining of NF200 and MBP was used to detect the regeneration of axons and myelin sheath of the distal damaged tissue. The number of regenerated axons and myelin sheaths showed that EA is a powerful tool that can be used to promote the regeneration of nerve...
fibers, compared with the model group, while the regeneration of the nerve fiber was significantly inhibited in the EG and ES group, compared with the EA group (Figure 4).

4.3. Exosomal miR-21 Participates in EA by Promoting the Proliferation of SC and the Expression of NTFs. **S-100α** is found in the SC cytoplasm and myelin sheath of peripheral nerves and functions as an objective morphological indicator that reflects the proliferation of SC in vivo. Nerve regeneration was indirectly evaluated through the proliferation of SC and the expression of NTFs (NGF, BDNF, GDNF). We observed that **S-100α**, NGF, BDNF, and GDNF expression levels were upregulated in the EA group, compared with that of the model group, while these expression levels were inhibited in the EG and ES group, compared with the EA group according to immunofluorescence staining (Figure 5).

4.4. Exosomal miR-21 Regulates Gene Expression Changes in the Distal Sciatic Nerve. Exosomes secreted from local SC were labeled using GFP through lentiviral transfection. Colocalization of NF200 and GFP can be used as evidence of the secretion of exosomes by SC can be transferred and internalized to axons (Figure 6(a)). Next, we isolated exosomes that overexpressed miR-21 or normal exosomes from the cell supernatant of SC with or without lentiviral infection. After PCR verification (Supplementary Figure S3), these exosomes were injected into the injury region of the model. At 21 d, we found that the expression of miR-21 was elevated in serum exosomes and injured tissues in the EXO-MC and EXO-miR-21 groups, compared with that of the model group, and the increase in the EXO-miR-21 group was more pronounced than that of the EXO-MC group (Figures 6(b) and 6(c)). The expression of SPRY2 was the lowest in the EXO-miR-21 group, and the trend of SPRY2 expression showed a negative correlation with miR-21 (Figures 6(d) and 6(e)). Injection of exosomes that overexpressed miR-21 significantly enhanced the expression level of GAP43 and DNMT3A (Figures 6(f) and 6(g)). The expression of GAP43 and DNMT3A showed a positive correlation with miR-21 (Figure 6(h)).

4.5. Exosomal miR-21 Participates in Nerve Regeneration and Repair. Symptoms of plantar ulcers were alleviated in the EXO-MC and EXO-miR-21 group, compared with that of the model group (Supplementary Figure S4). The sciatic nerve function recovery index improved after 21 d of EXO-MC and EXO-miR-21 treatment, as indicated through changes in NCV, SFI, and WWRG. In addition, NCV, SFI, and WWRG values in the EXO-miR-21 group were dramatically higher than those in the EXO-MC group (Figures 7(a)–7(d)). Immunofluorescence staining of NF200 and MBP indicated that EXO-MC and EXO-miR-21 were involved in promoting the regeneration of nerve fibers, compared with the model group. Furthermore, the number of NF200 and MBP positive cells was greater in the EXO-miR-21 group, compared to the EXO-MC group (Figures 8(a)–8(d)).

4.6. Exosomal miR-21 Participates in the Proliferation of SC and the Expression of NTFs. Since SC proliferation and NTF secretions play a key role in peripheral nerve
regeneration, we detected the proliferation of SC and the expression of NTFs using immunofluorescence staining. EXO-MC treatment significantly promoted the expression of S-100\(\alpha\), which indicated that EXO-MC is involved in the proliferation of SC after PNI. There were more S-100\(\alpha\) positive cells in the injured nerve of rats treated using EXO-miR-21, compared with the EXO-MC group. Although the expressions of NGF, BDNF, and GDNF were upregulated in the EXO-MC group, levels were much higher in the EXO-miR-21 group, demonstrating that EXO-miR-21 injection not only further enhanced the proliferation of SC but also promoted levels of NTFs, including NGF, BDNF, and GDNF probably by transferring much more miR-21 (Figure 9).

4.7. SC-Derived Exosomal miR-21 Promotes Neurite Outgrowth In Vitro.

The exosomes secreted by SC were labeled using GFP and were cocultivated with NG108-15 cells for 3 d. Double-immunofluorescence staining indicated that the exosomes secreted by SC could be taken up by neurons (Supplementary Figure S5). Moreover, we found that SC-derived exosomal miR-21 could be taken up by neurons and their neurites using IF-FISH (Figure 10(a)). FBS without exosomes (FBS-EXO) were harvested after the exosomes were successfully removed (Supplementary Figure S6A) and were found to be positive for CD9 and CD63 (Supplementary Figure S6B). Neurons were treated with SC-derived exosomes, and the average and longest length of the neurites were increased in the NC + EXO group, compared with the NC group. The growth of neurites was attenuated when the expression of miR-21 was inhibited. Furthermore, the effects of EXO treatment were inhibited in the IN+EXO group, compared with the NC+EXO group (Figures 10(b)–10(d)). Taken together, SC-derived exosomal miR-21 promoted neurite outgrowth in vitro. In addition, the viability of NG108-15 cells in each group was detected using CCK8 assay, and viability of cells in the IN+EXO group was much lower than that of the NC+EXO group (Supplementary Figure S7).
5. Discussion

Although peripheral nerves have a reconstitutive ability, it is difficult to fully recover nerve function after PNI. EA is not only effective in treating PNI [53] but can also be used for the treatment of neuropathic pain [54] and central nervous disease [55]. Since miRNAs are closely associated with the development of PNI [15, 32, 33, 41, 56–59] and nerve repair,
Figure 6: Continued.
while exosomes are valuable carriers of miRNAs [60], our study focused on exosomal delivery of miR-21 to explore the effects of EA. Exosomes can minimize safety concerns associated with the administration of live cells as cell-free therapy and has a great therapeutic potential for the treatment of brain, heart, liver, lung, skin, and bone diseases [61]. Thus far, it has been identified that miR-21-5p contains exosomes derived from SC that can improve sensory neuron growth through the PTEN-PI3K pathway in vitro [62] and has the ability to ameliorate peripheral neuropathy in type 2 diabetes patients.

![Exosomal miR-21 regulates the gene expression levels in the distal sciatic nerve. (a) Immunofluorescence staining of NF200 (red) and GFP (green). The nuclei were visualized using DAPI (blue). The colocalization of axons and exosomes was marked with arrows. Bar = 25 μm. (b) Relative expression level of miR-21 in serum exosomes at 21 d. (c) Relative expression of miR-21 in injured tissue at 21 d. Relative expression level of SPRY2 (d), GAP43 (f), and DNMT3A (g). *P < 0.05; **P < 0.01 compared with the model group; #P < 0.05; ###P < 0.01 compared with the EXO-MC group. The relationship between miR-21 and SPRY2 (c) or that of GAP43 and DNMT3A (f) was summarized.](image)

![Exosomal miR-21 participates in the recovery of nerve function. NCV (affected side/intact side, (a)), SFI (b, c), and WWRG (affected side/intact side, (d)) were detected in each group. **P < 0.01 compared with the model group; #P < 0.05; ###P < 0.01 compared with the EXO-MC group.](image)
2 diabetic mice [63]. In addition, exosomal cargo, including miR-21, can regulate sensory neurons for macrophage communication after nerve trauma [42], indicating that exosomal miR-21 has the potential to mediate and treat PNI. Levels of the exosomal biomarkers, TSG101 and CD81, increased in the ischemic striatum after EA treatment [64], suggesting that EA may stimulate an increase in exosomes secreted. Therefore, the regulation of secretions and transfer

Figure 8: Exosomal miR-21 participates in the regeneration of nerve fibers. (a) Immunofluorescence staining of NF200 (green). Bar = 10 μm. (b) The number of NF200 positive cells, which was used to indicate the number of regenerated axons, was counted. *P < 0.05; **P < 0.01 compared with the model group; ###P < 0.01 compared with the EXO-MC group. (c) Immunofluorescence staining of MBP (green). Bar = 10 μm. (d) Statistics of the number of MBP positive cells, which was used to indicate the number of myelin sheaths. **P < 0.01 compared with the model group; ###P < 0.01 compared with the EXO-MC group.
Figure 9: Exosomal miR-21 participates in the proliferation of SC and the expression of NTFs. (a) Immunofluorescence staining of S-100α (green). The nuclei were visualized using DAPI (blue) staining. Bar = 10 μm. (b) Immunofluorescence staining of NGF, BDNF, and GDNF (green). Bar = 10 μm. (c) Mean fluorescence intensity of S-100α. *P < 0.05; **P < 0.01 compared with the model group; ##P < 0.01 compared with the EXO-MC group. Mean fluorescence intensity of NGF, BDNF, and GDNF (d–f). **P < 0.01 compared with the model group; #P < 0.01 compared with the EXO-MC group.
**Figure 10:** SC-derived exosomal miR-21 promotes neurite outgrowth *in vitro*. (a) miR-21 in situ hybridizations (red) and immunofluorescence staining of βIII-tubulin (blue) showed that exosomes secreted by SC could be taken up by neurons. miR-21 was found in the neuron cell body (indicated by arrows) and neuronal processes (shown in the square). Bar = 25 μm. (b) Immunofluorescence staining of βIII-tubulin (red) to detect NG108-15 protrusion growth. Bar = 50 μm. (c) The average protrusion length of the neurons were calculated. **P < 0.01** compared with the NC group; ***P < 0.01** compared with the NC + EXO group; &&P < 0.01 compared with the IN group. (d) The length of the longest protrusion was calculated. **P < 0.01** compared with the NC group; ***P < 0.01** compared with the NC + EXO group; &P < 0.05, compared with the IN group.
of exosomes between cells may be one of the principal mechanisms of EA treatment.

We first explored whether the release of exosomes and the delivery of miR-21 by exosomes in the PNI model rats were affected by EA. The acupoints, “Huantiao” (GB30) and “Zusanli” (ST36), were selected in our study based on basic traditional Chinese medicine theory. “Huantiao” (GB30) is located at the foot of the Shaoyang gallbladder meridian and intersects with the foot bladder meridian. EA can invigorate blood in the lower limbs. “Zusanli” (ST36) is located in the foot Yangming stomach meridian and performs many functions, such as health care and strongness. PNI belongs to the dysfunction syndrome in Chinese medicine. Huangdi Neijing indicates that the treatment of dysfunction is based on Yangming. It was found that the expression level of miR-21 in serum exosomes was lower than that of the model group at 1 week after EA treatment but was higher at 3 weeks, while miR-21 expression in injured local nerves in the EA group was consistently elevated, compared with the model group. It showed that EA inhibits the release of serum exosomal miR-21 in PNI rats during the early stage of PNI, while promoting its release during later stages. We speculated that EA may promote the transfer of exosomal miR-21 from serum to injured tissue. Since SC is a unique type of glia cell in the peripheral nervous system and exosomes are the main mediators of glia-neuron communication, the lentivirus of pCT-CD63-gPDDeGFP was used for green fluorescence labeling of the exosome, which may be secreted by SC and double-immunofluorescence staining showed that these exosomes can be taken up by axons.

Since EA exerts a dual-directional regulatory effect on serum exosomal miR-21, we explored whether exosomal miR-21 was involved in the promotion of nerve regeneration exerted by EA. GW4869 is a non-competitive sphingomyelinase inhibitor that inhibits the release of exosomes [65, 66]. Intrapertioneal injection of GW4869 can inhibit exosomes in circulation [67], and there were no adverse effects reported following the use of GW4869 [68, 69]. The miR-21-5p-sponge-lentivirus was used to inhibit the expression of miR-21 in the injured nerve tissue, which included exosome-derived miR-21. Based on the sciatic nerve function recovery index and immunofluorescence staining of NF200, MBP, S-100a, and NTFs, we proved that EA effectively promoted the recovery of nerve function after PNI. However, the reduction in circulatory exosomal release or miR-21 expression in the local injured tissue impaired the effect of EA. Therefore, the delivery of miR-21 by exosomes may be a key mechanism by which the effect of EA therapy is exerted. Based on this, we further tested whether SC exosomes overexpressing miR-21 were conducive to the recovery of PNI. The exosomes secreted by normal SC showed an obvious ability to promote the recovery of nerve function, and interestingly, injection of exosomes overexpressing miR-21 provided more encouraging outcomes. In addition, exosomal miR-21 secreted by SC could promote neurite outgrowth in vitro. Taken together, SC-derived exosomal miR-21 plays a significant role in the promotion of the repair effect exerted by EA, and exosomes may be potential carriers and transporters of miR-21 mediated by EA after PNI.

As an extensively studied miRNA, miR-21 can mediate inflammation [70], oxidative stress [71], cell apoptosis [72], proliferation [73], and regulate multiple signal pathways, including the protein kinase B (AKT) signaling pathway [74, 75], extracellular regulated protein kinases (ERK) signaling pathway [76, 77], and nuclear factor kappa-B (NF-κB) [78]. Plenty of studies have proven that miR-21 participates in the occurrence and development of tumors [79, 80], cardiovascular [81] and lung diseases [82, 83], glaucoma intraocular pressure [84], age-related skin wound healing [85], sepsis, and acute kidney injury [86]. Moreover, it is expected to be a potential marker for the diagnosis of diseases, such as colon cancer [87], liver cancer or hepatitis severity [88], colorectal cancer [89], and lung adenocarcinoma [90]. The expression of miR-21 was significantly elevated at 1, 4, 7, and 14 days after PNI and was able to regulate the gene expression of the sciatic nerve stump [91]. In fact, miR-21 exerted a protective effect on central neuron apoptosis [92]. Moreover, miR-21 could promote the proliferation of SC [43], inhibiting SC apoptosis [93], and enhancing the differentiation of stem cells towards SC. In this study, we found that miR-21 showed a significant negative correlation with its target gene, SPRY2, during PNI and the repair process. miR-21 can promote the repair of nerve fibers by directly targeting SPRY2 [40], and the knockdown of SPRY2 can enhance axonal regeneration of DRG neurons [95]. However, its in-depth mechanisms need to be further explored. GAP43 is related to neuronal development and plasticity [96]. It can support long-distance axon growth [97], and its deficiency can cause abnormal neuron pathfinding [98]. DNMT3A plays a significant role in the regulation of neuronal function and is essential for the synaptic plasticity of the central nervous system [99]. A lack of DNMT3A can lead to a reduction of motor neurons, degeneration of the nervous system, and defects of neuromuscular functions [100]. GAP43 [101, 102] and DNMT3A [103] are proteins associated with axon growth. In this study, we found that miR-21 was positively correlated with GAP43 and DNMT3A expression levels, while this potential link remains to be further elucidated.

As an SC cell line, RSC96 has been used in many studies [104–107], and results of experiments conducted on it are consistent with primary SC in common cell experiments [108, 109]. NG108-15 cells have been widely used as neuron cell lines [102, 110–113] to imitate motor neuron-like peripheral neurons to observe the growth of neurites using βIII-tubulin staining [102] in vitro. At present, we use these two cell lines to harvest sufficient exosomes and reduce the difficulty of the use of neuron culture. However, reliability verification of the primary cells awaits further investigation. As a carrier, exosomes protect their contents and transfer their cargo to target cells to exert certain functions [114]. Exosomes can be used to avoid the immune response, cancer risk, and ethical issues, compared with cell therapy [115]. Interestingly, we can transform and modify exosomes and turn them into handler “weapons” for disease treatment. For example, cells can be modified to secrete more exosomes
using specific RNA packages [116]. Cell nano-perforation can stimulate cells to produce up to 50 times more functional exosomes, which are equally effective, even in cells with low basal secretion levels [117]. We can also learn from the production and action methods of exosomes to continuously squeeze cells through a nano-sized filter to obtain exosome-mimetic nanovesicles. The resulting output was 100 times higher than that of exosomes produced in a traditional way and exerted the same functions [118, 119]. All these results demonstrate that exosomes have an immense potential as a novel method of treatment for PNI, especially after being modified.

However, this study has certain limitations: miR-21 can regulate many signaling pathways, such as the PI3K/Akt and Wnt/beta-catenin pathways, which are involved in the repair of neuron injury [62]; therefore, the involvement of these signaling pathways should be investigated further. We found that miR-21 expression levels in the location of injury in the exosome group was higher than that of the control group in vivo at 21 days postsurgery. However, it needs to be investigated whether sustained elevated levels of miR-21 can still promote the repair of peripheral nerves, and the dosage and administration route of miR-21 needs to be further verified. In addition, it is better to verify these details using experiments conducted on primary cells in vitro. Moreover, exosomes exist not only in the SC but also in the sciatic nerve itself and serum, which are the major origins of elevated levels of miR-21 expression in the local injury nerve and are worth exploring. Exosomes can mediate the transmission of many noncoding RNAs and proteins, including miR-21 [50], and the clarification of phenotypic differences and functional specificity of exosomes secreted from SC, serum and axon would be of great significance. At the same time, the specific mechanism by which miR-21 promotes nerve repair, such as the effects of miR-21 on SC differentiation, the guidance of newborn axons, myelin clearance, and the recruitment of macrophages, needs to be elucidated further. Meanwhile, exosomes can be combined with material science to create specific vescus and slow release treatments that would be of immense value for the development of other methods of treatment in the future.

Taken together, our results demonstrated the mechanism by which EA exerts its effects from the perspective of exosomal delivery of miR-21 and provides a theoretical basis for exosomal miR-21 as a novel method of PNI therapy.

**Data Availability**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Conflicts of Interest**

The authors declare no conflict of interest.

**Authors’ Contributions**

Hai-dong Guo and Shui-jin Shao conceived and designed the experiments. Yu-pu Liu and Yi-duo Yang were responsible for the experiment and figures and prepared the manuscript. Fang-fang Mou and Jing Zhu collected and analyzed the data. Guo-hong Cui was responsible for the collection and analysis of the data. Han Li, Tian-tian Zhao, and Yue Zhao contributed to the collection of the data. Shui-jin Shao provided materials and financial support. Guo-hong Cui and Hai-dong Guo reviewed and revised the manuscript. Yu-pu Liu and Yi-duo Yang contributed equally to this work.

**Acknowledgments**

This work was supported by grants from the National Science Foundation of China (No. 81873357 and No. 82174120), the Shanghai Talent Development Funding Scheme (No. 2019090), and the Natural Science Foundation of Shanghai (No. 21ZR1463100).

**Supplementary Materials**

Supplementary Figure S1: construction of PNI model of rat. (A) The sciatic nerve was dissociated. (B) After cutting the sciatic nerve, the epineurium on both sides of the stumps were sutured. Supplementary Figure S2: the general condition of the affected foot of rats was observed after being treated by EA EG or ES. Supplementary Figure S3: the expression of miR-21 in exosomes was detected by RT-qPCR. **P < 0.01, compared with the EXO-MC group. Supplementary Figure S4: the general condition of the affected foot of rats was observed after being treated by exosomes. Supplementary Figure S5: βIII-Tubulin (red) and GFP (green) showed that exosomes secreted by SC were taken up by NG108-15 cells. Nuclei were visualized with Hoechst 33342 (blue). The upper arrow showed that the SC exosomes entered into the neuron processes, and the lower arrow showed that the SC exosomes were still outside the neuron. Bar = 50 μm. Supplementary Figure S6: exosomal markers CD9 and CD63 were detected by WB. Supplementary Figure S7: CCK-8 detection of cell viability in each group of NG108-15. **P < 0.01, compared with the NC group; ##P < 0.01, compared with the NC+EXO group; &&P < 0.01, compared with the IN group. (Supplementary Materials)

**References**

[1] S. L. Guo, Z. Y. Zhang, Y. Xu et al., "Bone marrow-derived, neural-like cells have the characteristics of neurons to protect the peripheral nerve in microenvironment," Stem Cells International, vol. 2015. Article ID 941625, 9 pages, 2015.
[2] A. F. Peritore, R. Siracusa, R. Fusco et al., "Ultramicronized palmitoylethanolamide and paracetamol, a new association to relieve hyperalgesia and pain in a sciatic nerve injury model in rat," International Journal of Molecular Sciences, vol. 21, no. 10, p. 3509, 2020.
[3] M. Hsu, H. Liao, V. A. Truong et al., "CRISPR-based activation of endogenous neurotrophic genes in adipose stem cell sheets to stimulate peripheral nerve regeneration," Theranostics, vol. 9, no. 21, pp. 6099–6111, 2019.
[4] J. M. Hendry, M. C. Alvarez-Veronesi, E. Placheta, J. J. Zhang, T. Gordon, and G. H. Borschel, "ErbB2 blockade with
Herceptin (trastuzumab) enhances peripheral nerve regeneration after repair of acute or chronic peripheral nerve injury,” *Annals of Neurology*, vol. 80, no. 1, pp. 112–126, 2016.

[5] M. McAvoy, J. K. Tsovie, K. N. Vyas et al., “Flexible multielectrode array for skeletal muscle conditioning, acetylcholine receptor stabilization and epimyssial recording after critical peripheral nerve injury,” *Theranostics*, vol. 9, no. 23, pp. 7099–7107, 2019.

[6] J. Wang, L. Tian, L. He et al., “Lycium barbarum polysaccharide encapsulated poly lactico-glycolic acid nanofibers: cost effective herbal medicine for potential application in peripheral nerve tissue engineering,” *Scientific Reports*, vol. 8, no. 1, pp. 1–14, 2018.

[7] P. Caramitano, M. Mondelli, F. Logullo et al., “Traumatic peripheral nerve injuries: epidemiological findings, neuropathic pain and quality of life in 158 patients,” *Journal of the Peripheral Nervous System*, vol. 15, no. 2, pp. 120–127, 2010.

[8] C. N. Bruyns, J. Jaquet, S. Kalmijn, P. D. L. Kuypers, and S. E. R. Hovius, “Predictors for return to work in patients with median and ulnar nerve injuries,” *The Journal of Hand Surgery*, vol. 28, no. 1, pp. 28–34, 2003.

[9] F. Esen, L. A. Aktekin, H. Bodur, and C. Atan, “Etiological factors of traumatic peripheral nerve injuries,” *Neurology India*, vol. 57, no. 4, p. 434, 2009.

[10] R. Y. Torres and G. E. Miranda, “Epidemiology of traumatic peripheral nerve injuries evaluated by electrodiagnostic studies in a tertiary care hospital clinic,” *Boletin de la Asociacion Medica de Puerto Rico*, vol. 107, no. 3, pp. 79–84, 2015.

[11] M. P. Willand, E. Rosa, B. Michalski et al., “Electrical muscle stimulation elevates intramuscular BDNF and GDNF mRNA following peripheral nerve injury and repair in rats,” *Neuroscience*, vol. 334, pp. 93–104, 2016.

[12] C. M. Nichols, M. J. Brenner, L. K. Fox et al., “Effects of motor versus sensory nerve grafts on peripheral nerve regeneration,” *Experimental Neurology*, vol. 190, no. 2, pp. 347–355, 2004.

[13] C. Y. Ho, C. H. Yao, W. C. Chen, W. C. Shen, and D. T. Bau, “Electroacupuncture and acupuncture promote the rat’s transected median nerve regeneration,” *Evidence-based Complementary and Alternative Medicine*, vol. 2013, 7 pages, 2013.

[14] G. Dubrovsky, D. Ha, A. Thomas et al., “Electroacupuncture to increase neuronal stem cell growth,” *Medical Acupuncture*, vol. 32, no. 1, pp. 16–23, 2020.

[15] Y. P. Liu, Z. R. Luo, C. Wang et al., “Electroacupuncture promoted nerve repair after peripheral nerve injury by regulating miR-1b and its target brain-derived neurotrophic factor,” *Frontiers in Neuroscience*, vol. 14, article 525144, 2020.

[16] L. N. Hu, J. X. Tian, W. Gao et al., “Electroacupuncture and mibozhibon promote regeneration of injured sciatic nerve through Schwann cell proliferation and nerve growth factor secretion,” *Neural Regeneration Research*, vol. 13, no. 3, pp. 477–483, 2018.

[17] D. H. Chitwood and M. C. Timmermans, “Small RNAs are on the move,” *Nature*, vol. 467, no. 7316, pp. 415–419, 2010.

[18] H. Zhai and J. Ju, “Implications of microRNAs in colorectal cancer development, diagnosis, prognosis, and therapeutics,” *Frontiers in Genetics*, vol. 2, p. 78, 2011.

[19] S. Griffiths-Jones, H. K. Saini, S. van Dongen, and A. J. Enright, “MiRBase: tools for microRNA genomics,” *Nucleic Acids Research*, vol. 36, suppl_1, pp. D154–D158, 2007.

[20] K. D. Taganov, M. P. Boldin, and D. Baltimore, “MicroRNAs and immunity: tiny players in a big field,” *Immunity*, vol. 26, no. 2, pp. 133–137, 2007.

[21] D. P. Bartel, “MicroRNAs: target recognition and regulatory functions,” *Cell*, vol. 136, no. 2, pp. 215–233, 2009.

[22] A. V. Das and R. M. Pillai, “Implications of miR cluster 143/145 as universal anti-oncomiRs and their dysregulation during tumorigenesis,” *Cancer Cell International*, vol. 15, no. 1, pp. 1–12, 2015.

[23] M. Brighenti, “MicroRNA and MET in lung cancer,” *Annals of Translational Medicine*, vol. 3, no. 5, 2015.

[24] A. Krek, D. Grün, M. N. Poy et al., “Combinatorial microRNA target predictions,” *Nature Genetics*, vol. 37, no. 5, pp. 495–500, 2005.

[25] R. C. Friedman, K. K. Farh, C. B. Burge, and D. P. Bartel, “Most mammalian mRNAs are conserved targets of microRNAs,” *Genome Research*, vol. 19, no. 1, pp. 92–105, 2009.

[26] R. Zhang, L. Lao, K. Ren, and B. M. Berman, “Mechanisms of acupunture–electroacupuncture on persistent pain,” *Anesthesiology*, vol. 120, no. 2, pp. 482–503, 2014.

[27] J. Wang, L. Yao, X. Wu et al., “Protection against doxorubicin-induced cardiotoxicity through modulating iNOS/ARG2 balance by electroacupuncture at PC6,” *Oxidative Medicine and Cellular Longevity*, vol. 2021, 2017 pages, 2021.

[28] H. Xu, Y. Wang, and Y. Luo, “OTULIN is a new target of EA treatment in the alleviation of brain injury and glial cell activation via suppression of the NF-κB signalling pathway in acute ischaemic stroke rats,” *Molecular Medicine*, vol. 27, no. 1, pp. 1–19, 2021.

[29] N. Yang, J. Yang, Y. Ye et al., “Electroacupuncture ameliorates intestinal inflammation by activating α7nACHr-mediated JAK2/STAT3 signaling pathway in postoperative ileus,” *Theranostics*, vol. 11, no. 9, pp. 4078–4089, 2021.

[30] L. Chen, X. Huang, L. Wang et al., “Electroacupuncture reduces oocyte number and maintains vascular barrier against ovarian hyperstimulation syndrome by regulating CD200,” *Frontiers in Cell and Developmental Biology*, vol. 9, p. 317, 2021.

[31] S. Li, B. Yu, S. Wang et al., “Identification and functional analysis of novel micro-RNAs in rat dorsal root ganglia after sciatic nerve resection,” *Journal of Neuroscience Research*, vol. 90, no. 4, pp. 791–801, 2012.

[32] S. Li, X. Wang, Y. Gu et al., “Let-7 microRNAs regenerate peripheral nerve regeneration by targeting nerve growth factor,” *Molecular Therapy*, vol. 23, no. 3, pp. 423–433, 2015.

[33] C. Yao, X. Shi, Z. Zhang et al., “Hypoxia-induced upregulation of miR-132 promotes Schwann cell migration after sciatic nerve injury by targeting PRKAG3,” *Molecular Neurobiology*, vol. 53, no. 8, pp. 5129–5139, 2016.

[34] S. Yi, Y. Yuan, Q. Chen et al., “Regulation of Schwann cell proliferation and migration by miR-1 targeting brain-derived neurotrophic factor after peripheral nerve injury,” *Scientific Reports*, vol. 6, no. 1, p. 29121, 2016.

[35] A. J. Giraldez, R. M. Cinalli, M. E. Glaser et al., “MicroRNAs regulate brain morphogenesis in zebrafish,” *Science*, vol. 308, no. 5723, pp. 833–838, 2005.

[36] A. M. Krichevsky, K. C. Sonntag, O. Isacson, and K. S. Kosik, “Specific microRNAs modulate embryonic stem cell-derived neurogenesis,” *Stem Cells*, vol. 24, no. 4, pp. 857–864, 2006.
[37] N. Hori, M. Narita, A. Yamashita et al., “Changes in the expression of IL-6-mediated microRNAs in the dorsal root ganglion under neuropathic pain in mice,” *Synapse*, vol. 70, no. 8, pp. 317–324, 2016.

[38] C. Rau, J. C. Jeng, S. Jeng et al., “Entrapment neuropathy results in different microRNA expression patterns from denervation injury in rats,” *BMC Musculoskeletal Disorders*, vol. 11, no. 1, pp. 1–9, 2010.

[39] B. Yu, S. Zhou, T. Qian, Y. Wang, F. Ding, and X. Gu, “Altered microRNA expression following sciatic nerve resection in dorsal root ganglia of rats,” *Acta Biochimica et Biophysica Sinica*, vol. 43, no. 11, pp. 909–915, 2011.

[40] I. T. Strickland, L. Richards, F. E. Holmes, D. Wynick, J. B. Uney, and L. F. Wong, “Axotomy-induced miR-21 promotes axon growth in adult dorsal root ganglion neurons,” *PLoS One*, vol. 6, no. 8, article e23423, 2011.

[41] S. Zhou, S. Zhang, Y. Wang et al., “MiR-21 and miR-222 inhibit apoptosis of adult dorsal root ganglion neurons by repressing TIMP3 following sciatic nerve injury,” *Neuroscience Letters*, vol. 586, pp. 43–49, 2015.

[42] R. Simeoli, K. Montague, H. R. Jones et al., “Exosomal cargo including microRNA regulates sensory neuron to macrophage communication after nerve trauma,” *Nature Communications*, vol. 8, no. 1, p. 1778, 2017.

[43] X. J. Ning, X. H. Lu, J. C. Luo et al., “Molecular mechanism of microRNA-21 promoting Schwann cell proliferation and axon regeneration during injured nerve repair,” *RNA Biology*, vol. 17, no. 10, pp. 1508–1519, 2020.

[44] K. R. Jessen, R. Mirsky, and A. C. Lloyd, “Schwann cells: development and role in nerve repair,” *Cold Spring Harbor Perspectives in Biology*, vol. 7, no. 7, article a20487, 2015.

[45] E. Endzelis, V. Melne, Z. Kalnina et al., “Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review,” *Molecular Cancer*, vol. 15, no. 1, p. 41, 2016.

[46] M. Krause, A. Samoylenko, and S. J. Vainio, “Exosomes as renal inductive signals in health and disease, and their application as diagnostic markers and therapeutic agents,” *Frontiers in Cell and Developmental Biology*, vol. 3, p. 65, 2015.

[47] H. Yu, T. Sun, J. An et al., “Potential roles of exosomes in Parkinson’s disease: from pathogenesis, diagnosis, and treatment to prognosis,” *Frontiers in Cell and Developmental Biology*, vol. 8, p. 86, 2020.

[48] R. Lopez-Leal and F. A. Court, “Schwann cell exosomes mediate neuron-glia communication and enhance axonal regeneration,” *Cytoskeletal and Molecular Neurobiology*, vol. 36, no. 3, pp. 429–436, 2016.

[49] D. Fröhlich, W. P. Kuo, C. Frühbeis et al., “Multifaceted effects of oligodendroglial exosomes on neurons: impact on neuronal firing rate, signal transduction and gene regulation,” *Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences*, vol. 369, no. 1652, article 20130510, 2014.

[50] M. S. Fayazi, M. Sheykhsas, S. Soleimani Asl, and R. Najafi, “Stem cell-derived exosomes: a new strategy of neurodegenerative disease treatment,” *Molecular Neurobiology*, vol. 58, no. 7, pp. 3494–3514, 2021.

[51] Z. Su, Y. Yuan, M. Yu, Y. Liu, J. D. Klein, and X. H. Wang, “Electrically stimulated acupuncture increases renal blood flow through exosome-carried miR-181,” *American Journal of Physiology-Renal Physiology*, vol. 315, no. 6, pp. F1542–F1549, 2018.

[52] Y. Shou, L. Hu, W. Zhang, Y. Gao, P. Xu, and B. Zhang, “Determination of electroacupuncture effects on circRNAs in plasma exosomes in diabetic mice: an RNA-sequencing approach,” *Evidence-based Complementary and Alternative Medicine*, vol. 2019, Article ID 7543049, 15 pages, 2019.

[53] J. Wu, Y. Lu, X. Hua, S. J. Ma, C. L. Shan, and J. G. Xu, “Cortical remodeling after electroacupuncture therapy in peripheral nerve repairing model,” *Brain Research*, vol. 1690, pp. 61–73, 2018.

[54] J. Wan, S. Nan, J. Liu et al., “Synaptotagmin 1 is involved in neuropathic pain and electroacupuncture-mediated analgesic effect,” *International Journal of Molecular Sciences*, vol. 21, no. 3, p. 968, 2020.

[55] J. Yu, D. Min, Y. Bai, L. Qu, T. Zou, and S. Wang, “Electroacupuncture alleviates Parkinson disease and regulates the expression of brain-gut peptides,” *Experimental Animals*, vol. 69, no. 4, pp. 448–460, 2020.

[56] S. Zhou, R. Gao, W. Hu et al., “MiR-9 inhibits Schwann cell migration by targeting Cthrc1 following sciatic nerve injury,” *Journal of Cell Science*, vol. 127, Part 5, pp. 967–976, 2014.

[57] G. Wu, X. Li, M. Li, and Z. Zhang, “Long non-coding RNA MALAT1 promotes the proliferation and migration of Schwann cells by elevating BDNF through sponging miR-129-5p,” *Experimental Cell Research*, vol. 390, no. 1, article 111937, 2020.

[58] X. Liu, X. Cui, G. Guan, Y. Dong, and Z. Zhang, “MicroRNA-192-5p is involved in nerve repair in rats with peripheral nerve injury by regulating XIAP,” *Cell Cycle*, vol. 19, no. 3, pp. 326–338, 2020.

[59] Y. P. Liu, P. Xu, C. X. Guo et al., “MiR-1b overexpression suppressed proliferation and migration of RSC96 and increased cell apoptosis,” *Neuroscience Letters*, vol. 687, pp. 137–145, 2018.

[60] M. N. Asim, M. I. Malik, C. Zehe, J. Trygg, A. Dengel, and S. Ahmed, “MirLocPredictor: a ConvNet-based multi-label microRNA subcellular localization predictor by incorporating k-Mer positional information,” *Genes*, vol. 11, no. 12, p. 1475, 2020.

[61] J. Shi, Y. Zhao, Z. Niu et al., “Mesenchymal stem cell-derived small extracellular vesicles in the treatment of human diseases: progress and prospect,” *World Journal of Stem Cells*, vol. 13, no. 1, pp. 49–63, 2021.

[62] M. Cong, M. Shen, X. Wu et al., “Improvement of sensory neuron growth and survival via negatively regulating PTEN by miR-21-5p-contained small extracellular vesicles from skin precursor-derived Schwann cells,” *Stem Cell Research & Therapy*, vol. 12, no. 1, p. 80, 2021.

[63] L. Wang, M. Chopp, A. Szalad et al., “Exosomes derived from Schwann cells ameliorate peripheral neuropathy in type 2 diabetic mice,” *Diabetes*, vol. 69, no. 4, pp. 749–759, 2020.

[64] S. Zhang, T. Jin, L. Wang et al., “Electro-acupuncture promotes the differentiation of endogenous neural stem cells via exosomal microRNA 146b after ischemic stroke,” *Frontiers in Cellular Neuroscience*, vol. 14, p. 223, 2020.

[65] H. Zhou, X. Li, Y. Yin et al., “The proangiogenic effects of extracellular vesicles secreted by dental pulp stem cells derived from periodontally compromised teeth,” *Stem Cell Research & Therapy*, vol. 11, no. 1, p. 110, 2020.
[66] L. Zhu, J. Zang, B. Liu et al., “Oxidative stress-induced RAC autophagy can improve the HUVEC functions by releasing exosomes,” *Journal of Cellular Physiology*, vol. 235, no. 10, pp. 7392–7409, 2020.

[67] F. Xu, J. Y. Zhong, X. Lin et al., “Melatonin alleviates vascular calcification and ageing through exosomal miR-204/miR-211 cluster in a paracrine manner,” *Journal of Pineal Research*, vol. 68, no. 3, article e12631, 2020.

[68] N. Tabatadze, A. Savonenko, H. Song, V. V. R. Bandaru, M. Chu, and N. J. Haughey, "Inhibition of neutral sphingomyelinase-2 perturbs brain sphingolipid balance and spatial memory in mice," *Journal of Neuroscience Research*, vol. 88, no. 13, pp. 2940–2951, 2010.

[69] M. B. Dinkins, S. Dasgupta, G. Wang, G. Zhu, and E. Bieberich, "Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer’s disease," *Neurobiology of Aging*, vol. 35, no. 8, pp. 1792–1800, 2014.

[70] F. J. Shedly, "Turning 21: induction of miR-21 as a key switch in the inflammatory response," *Frontiers in Immunology*, vol. 6, p. 19, 2015.

[71] V. L. Nasci, S. Chuppa, L. Griswold, K. A. Goodreau, R. K. Dash, and A. J. Kriegel, "MiR-21-5p regulates mitochondrial respiration and lipid content in H9C2 cells," *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 316, no. 3, pp. H710–H721, 2019.

[72] X. Fu, Y. He, X. Wang et al., "Overexpression of miR-21 in stem cells improves ovarian structure and function in rats with chemotherapy-induced ovarian damage by targeting PDCD4 and PTEN to inhibit granulosa cell apoptosis," *Stem Cell Research & Therapy*, vol. 8, no. 1, p. 187, 2017.

[73] L. Zhang, L. Yu, Y. Liu, S. Wang, Z. Hou, and J. Zhou, "MiR-21-5p promotes cell proliferation by targeting BCL11B in Thp-1 cells," *Oncology Letters*, vol. 21, no. 2, p. 119, 2020.

[74] H. Y. Liu, Y. Y. Zhang, B. L. Zhu et al., "MiR-21 regulates the proliferation and apoptosis of ovarian cancer cells through PTEN/P13K/AKT," *European Review for Medical and Pharmacological Sciences*, vol. 23, no. 10, pp. 4149–4155, 2019.

[75] L. Ma, Y. Zheng, X. Tang et al., "MiR-21-3p inhibits autophagy of bovine granulosa cells by targeting VEGFA via P13K/AKT signaling," *Reproduction*, vol. 158, no. 5, pp. 441–452, 2019.

[76] D. Li, C. Mao, E. Zhou et al., "MicroRNA-21 mediates a positive feedback on angiotensin II-induced myofibroblast Transformation," *Journal of Inflammation Research*, vol. 13, pp. 1007–1020, 2020.

[77] F. Liu and B. Yang, "Double-targeted knockdown of miR-21 and CXCR4 inhibits malignant glioma progression by suppression of the P13K/AKT and Raf/MEK/ERK pathways," *BioMed Research International*, vol. 2020, Article ID 7930160, 17 pages, 2020.

[78] G. Li, Y. Yang, S. Xu, M. He, and Z. Zhang, "MiR-21-5p inhibits the progression of human chondrosarcoma by regulating CCR7/STAT3/NF-kB pathway," *Connective Tissue Research*, vol. 62, no. 3, pp. 313–324, 2021.

[79] S. Wang, F. Ma, Y. Feng, T. Liu, and S. He, "Role of exosomal miR21 in the tumor microenvironment and osteosarcoma tumorigenesis and progression (review)," *International Journal of Oncology*, vol. 56, no. 5, pp. 1055–1063, 2020.

[80] X. Wei, X. You, J. Zhang, and C. Zhou, "miR-21 inhibitor facilitates the anticancer activity of doxorubicin loaded nano-meter in melanoma," *Oncology Reports*, vol. 42, no. 1, pp. 414–424, 2019.

[81] J. Xiao, Y. Pan, X. H. Li et al., "Cardiac progenitor cell-derived exosomes prevent cardiomyocytes apoptosis through exosomal miR-21 by targeting PDCD4," *Cell Death & Disease*, vol. 7, no. 6, article e2277, 2016.

[82] R. Kumarswamy, I. Volkmann, and T. Thum, "Regulation and function of miRNA-21 in health and disease," *RNA Biology*, vol. 8, no. 5, pp. 706–713, 2011.

[83] L. Li, L. Wei, Z. Han, and Z. Chen, "Mesenchymal stromal cells-derived exosomes alleviate ischemia/reperfusion injury in mouse lung by transporting anti-apoptotic miR-21-5p," *European Journal of Pharmacology*, vol. 852, pp. 68–76, 2019.

[84] C. Tan, M. Song, W. D. Stamer et al., "MiR-21-5p: a viable therapeutic strategy for regulating intraocular pressure," *Experimental Eye Research*, vol. 200, article 108197, 2020.

[85] S. Long, N. Zhao, L. Ge et al., "MiR-21 ameliorates age-associated skin wound healing defects in mice," *Journal of Gene Medicine*, vol. 20, no. 6, article e3022, 2018.

[86] W. Wei, Y. Y. Yao, H. Y. Bi, Z. Zhai, and Y. Gao, "MiR-21 protects against lipopolysaccharide-stimulated acute kidney injury and apoptosis by targeting CDK6," *Annals of Translational Medicine*, vol. 8, no. 6, p. 303, 2020.

[87] F. Dehghan, S. Boozaipur, Z. Torabizadeh, and S. Alijanpour, "miR-21: a promising biomarker for the early detection of colon cancer," *Oncotargets and Therapy*, vol. -12, pp. 5601–5607, 2019.

[88] J. Zhang, D. Li, R. Zhang, P. Gao, R. Peng, and J. Li, "The miR-21 potential of serving as a biomarker for liver diseases in clinical practice," *Biochemical Society Transactions*, vol. 48, no. 5, pp. 2295–2305, 2020.

[89] G. Li, Q. Wang, Z. Li, and Y. Shen, "Serum miR-21 and miR-210 as promising non-invasive biomarkers for the diagnosis and prognosis of colorectal cancer," *Revista Espanola De Enfermedades Digestivas*, vol. 112, no. 11, pp. 832–837, 2020.

[90] S. Cui, S. Lou, W. Guo et al., "Prediction of MiR-21-5p in promoting the development of lung adenocarcinoma via PDZD2 regulation," *Medical Science Monitor*, vol. 26, article e923366, 2020.

[91] Y. Wang, S. Wang, and J. H. He, "Transcriptomic analysis reveals essential microRNAs after peripheral nerve injury," *Neural Regeneration Research*, vol. 16, no. 9, pp. 1865–1870, 2021.

[92] L. Wang, Z. Yin, F. Wang et al., "Hydrogen exerts neuroprotection by activation of the miR-21/P13K/AKT/GSK-3β pathway in an in vitro model of traumatic brain injury," *Journal of Cellular and Molecular Medicine*, vol. 24, no. 7, pp. 4061–4071, 2020.

[93] M. Yuan, X. Yang, D. Duscher et al., "Overexpression of microRNA-21-5p prevents the oxidative stress-induced apoptosis of RSC26 cells by suppressing autophagy," *Life Sciences*, vol. 256, article 118022, 2020.

[94] Y. Zhou, Y. Ni, K. Zhang et al., "MiR-21 promotes the differentiation of hair follicle-derived neural crest stem cells into Schwann cells," *Neural Regeneration Research*, vol. 9, no. 8, pp. 828–836, 2014.

[95] S. Jamsuwan, L. Klimaschewski, and B. Hausott, "Simultaneous knockdown of Sprouty2 and PTEN promotes axon elongation of adult sensory neurons," *Frontiers in Cellular Neuroscience*, vol. 13, p. 583, 2020.
[96] L. I. Benowitz and A. Routtenberg, “GAP-43: an intrinsic determinant of neuronal development and plasticity,” Trends in Neurosciences, vol. 20, no. 2, pp. 84–91, 1997.

[97] K. Goslin, D. J. Schreyer, J. P. Skene, and G. Banker, “Development of neuronal polarity: GAP-43 distinguishes axonal from dendritic growth cones,” Nature, vol. 336, no. 6200, pp. 672–674, 1988.

[98] S. M. Strittmatter, C. Fankhauser, P. L. Huang, H. Mashimo, and M. C. Fishman, “Neural pathfinding is abnormal in mice lacking the neuronal growth cone protein GAP-43,” Cell, vol. 80, no. 3, pp. 445–452, 1995.

[99] J. Feng, Y. Zhou, S. L. Campbell et al., “Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons,” Nature Neuroscience, vol. 13, no. 4, pp. 423–430, 2010.

[100] S. Nguyen, K. Meletis, D. Fu, S. Jhaveri, and R. Jaenisch, “Ablation of de novo DNA methyltransferase Dnmt3a in the nervous system leads to neuromuscular defects and shortened lifespan,” Developmental Dynamics: an official publication of the American Association of Anatomists, vol. 236, no. 6, pp. 1663–1676, 2007.

[101] M. A. Lopez-Verrilli, F. Picou, and F. A. Court, “Schwann cell-derived exosomes enhance axonal regeneration in the peripheral nervous system,” Glia, vol. 61, no. 11, pp. 1795–1806, 2013.

[102] R. C. Ching, M. Wiberg, and P. J. Kingdom, “Schwann cell-like differentiated adipose stem cells promote neurite outgrowth via secreted exosomes and RNA transfer,” Stem Cell Research & Therapy, vol. 9, no. 1, p. 266, 2018.

[103] L. Jia, M. Chopp, L. Wang, X. Lu, A. Szalad, and Z. G. Zhang, “Exosomes derived from high-glucose-stimulated Schwann cells promote development of diabetic peripheral neuropathy,” FASEB Journal, vol. 32, no. 12, pp. 6911–6922, 2018.

[104] E. Torres-Mejía, D. Trümbach, C. Kleeberger et al., “Sox2 controls Schwann cell self-organization through fibroactin fibrillogenesis,” Scientific Reports, vol. 10, no. 1, pp. 1–17, 2020.

[105] G. Monaco, R. Cholas, L. Salvatore, M. Madaghiele, and A. Sannino, “Sterilization of collagen scaffolds designed for peripheral nerve regeneration: effect on microstructure, degradation and cellular colonization,” Materials Science and Engineering: C, vol. 71, pp. 335–344, 2017.

[106] Y. Niu, F. J. Stadler, and M. Fu, “Biomimetic electrospun tubular PLLA/gelatin nanofiber scaffold promoting regeneration of sciatic nerve transection in SD rat,” Materials Science and Engineering: C, vol. 121, article 111858, 2021.

[107] J. An, X. Zhang, K. Jia et al., “Trichostatin A increases BDNF protein expression by improving XBP-1s/ATF6/GRP78 axis in Schwann cells of diabetic peripheral neuropathy,” Biomedicine & Pharmacotherapy, vol. 133, 2021.

[108] L. Qu, X. Liang, B. Gu, and W. Liu, “Quercetin alleviates high glucose-induced Schwann cell damage by autophagy,” Neuro Regeneration Research, vol. 9, no. 12, p. 1195, 2014.

[109] T. Gui, Y. Wang, L. Zhang, W. Wang, H. Zhu, and W. Ding, “Krüppel-like factor 6 rendered rat Schwann cell more sensitive to apoptosis via upregulating FAS expression,” PLoS One, vol. 8, no. 12, article e82449, 2013.

[110] P. J. Kingham, D. F. Kalbermatten, D. Mahay, S. J. Armstrong, M. Wiberg, and G. Terenghi, “Adipose-derived stem cells differentiate into a Schwann cell phenotype and promote neurite outgrowth in vitro,” Experimental Neurology, vol. 207, no. 2, pp. 267–274, 2007.

[111] A. K. Fu, F. C. Ip, K. O. Lai, K. W. K. Tsim, and N. Y. Ip, “Muscle-derived neurotrophin-3 increases the aggregation of acetylcholine receptors in neuron–muscle co-cultures,” Neuroreport, vol. 8, no. 18, pp. 3895–3900, 1997.

[112] A. Magaz, B. F. Spencer, J. G. Hardy, X. Li, J. E. Gough, and J. J. Blaker, “Modulation of neuronal cell affinity on PEDOT–PSS nonwoven silk scaffolds for neural tissue engineering,” ACS Biomaterials Science & Engineering, vol. 6, no. 12, pp. 6906–6916, 2020.

[113] J. Alexandre, R. Malheiro, D. Dias da Silva, H. Carmo, F. Carvalho, and J. P. Silva, “The synthetic cannabinoids THJ-2201 and 5F-PB22 enhance in vitro CB1 receptor-mediated neuronal differentiation at biologically relevant concentrations,” International Journal of Molecular Sciences, vol. 21, no. 17, p. 6277, 2020.

[114] J. P. Nederveen, G. Warnier, A. di Carlo, M. I. Nilsson, and M. A. Tarnopolsky, “Extracellular vesicles and exosomes: insights from exercise science,” Frontiers in Physiology, vol. 11, p. 1757, 2021.

[115] B. Yin, Q. Ma, C. Song et al., “Exosome-derived noncoding RNAs as a promising treatment of bone regeneration,” Stem Cells International, vol. 2021, 8 pages, 2021.

[116] R. Kojima, D. Bojar, G. Rizzi et al., “Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson’s disease treatment,” Nature Communications, vol. 9, no. 1, pp. 1–10, 2018.

[117] Z. Yang, J. Shi, J. Xie et al., “Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation,” Nature Biomedical Engineering, vol. 4, no. 1, pp. 69–83, 2020.

[118] S. C. Jang, O. Y. Kim, C. M. Yoon et al., “Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapy to malignant tumors,” ACS Nano, vol. 7, no. 9, pp. 7698–7710, 2013.

[119] T. R. Lunavat, S. C. Jang, L. Nilsson et al., “RNAi delivery by exosome-mimetic nanovesicles - Implications for targeting c-Myc in cancer,” Biomaterials, vol. 102, pp. 231–238, 2016.